- Home
- KOD vs CABA Comparison
KOD vs CABA Comparison
Compare KOD & CABA Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- KOD
- CABA
- Stock Information
- Founded
- KOD 2009
- CABA 2017
- Country
- KOD United States
- CABA United States
- Employees
- KOD N/A
- CABA N/A
- Industry
- KOD Biotechnology: Biological Products (No Diagnostic Substances)
- CABA Biotechnology: Biological Products (No Diagnostic Substances)
- Sector
- KOD Health Care
- CABA Health Care
- Exchange
- KOD Nasdaq
- CABA Nasdaq
- Market Cap
- KOD 115.0M
- CABA 118.8M
- IPO Year
- KOD 2018
- CABA 2019
- Fundamental
- Price
- KOD $3.77
- CABA $1.19
- Analyst Decision
- KOD Hold
- CABA Strong Buy
- Analyst Count
- KOD 3
- CABA 8
- Target Price
- KOD $9.00
- CABA $21.00
- AVG Volume (30 Days)
- KOD 468.9K
- CABA 643.9K
- Earning Date
- KOD 05-19-2025
- CABA 05-19-2025
- Dividend Yield
- KOD N/A
- CABA N/A
- EPS Growth
- KOD N/A
- CABA N/A
- EPS
- KOD N/A
- CABA N/A
- Revenue
- KOD N/A
- CABA N/A
- Revenue This Year
- KOD N/A
- CABA N/A
- Revenue Next Year
- KOD N/A
- CABA N/A
- P/E Ratio
- KOD N/A
- CABA N/A
- Revenue Growth
- KOD N/A
- CABA N/A
- 52 Week Low
- KOD $1.92
- CABA $0.99
- 52 Week High
- KOD $11.60
- CABA $13.50
- Technical
- Relative Strength Index (RSI)
- KOD 50.83
- CABA 43.45
- Support Level
- KOD $3.66
- CABA $1.11
- Resistance Level
- KOD $4.20
- CABA $1.41
- Average True Range (ATR)
- KOD 0.49
- CABA 0.11
- MACD
- KOD 0.00
- CABA 0.01
- Stochastic Oscillator
- KOD 25.14
- CABA 26.67
About KOD Kodiak Sciences Inc
Kodiak Sciences Inc is a biopharmaceutical company specializing in novel therapeutics to treat high-prevalence retinal diseases. The product candidate of the company is BLA, which is a novel antibody biopolymer conjugate, in treatment-naive subjects with neovascular wet AMD. The pipeline products of the company include Tarcocimab tedromer, KSI-501, and KSI-101.
About CABA Cabaletta Bio Inc.
Cabaletta Bio Inc is a clinical-stage biotechnology company focused on the discovery and development of engineered T cell therapies, and exploring their potential to provide a deep and durable, perhaps curative, treatment, for patients with B cell-mediated autoimmune diseases. Its proprietary technology utilizes Chimeric AutoAntibody Receptor, or CAART cells that are designed to selectively bind and eliminate only specific B cells that produce disease-causing autoantibodies, or pathogenic B cells, while sparing normal B cells. Its CABA platform encompasses two strategies CARTA (chimeric antigen receptor T cells for autoimmunity) and CAART (chimeric autoantibody T cells) has the potential to be applied across a broad range of autoimmune diseases.